Alumis Inc. Common Stock (ALMS) Stock
NASDAQ · ALMS
7.06
Fundamentals
Market cap
$918.99M
Price / Earnings ratio
-2.1x
Price / Sales ratio
127.5x
Price / Book ratio
2.1x
Return on assets
-44.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Stocktwits
ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?
NeutralALMSSeptember 1, 2026
StocktwitsNeutral
ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?
ALMS

MarketBeat
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise
NeutralALMSSeptember 1, 2026
MarketBeatNeutral
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise
ALMS

Reuters
Alumis eyes late-stage lupus study despite trial miss
NeutralALMSSeptember 1, 2026
ReutersNeutral
Alumis eyes late-stage lupus study despite trial miss
ALMS

Zacks Investment Research
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
NeutralALMSAugust 11, 2026
Zacks Investment ResearchNeutral
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
ALMS
Technicals
OscillatorsNeutral5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral1
Buy4
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
29M19M10M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
494M326M163M0
Revenue to Profit
2025$24.1M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-243.3M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Stocktwits
ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?
NeutralALMSSeptember 1, 2026
StocktwitsNeutral
ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?
ALMS

MarketBeat
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise
NeutralALMSSeptember 1, 2026
MarketBeatNeutral
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise
ALMS

Reuters
Alumis eyes late-stage lupus study despite trial miss
NeutralALMSSeptember 1, 2026
ReutersNeutral
Alumis eyes late-stage lupus study despite trial miss
ALMS

Zacks Investment Research
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
NeutralALMSAugust 11, 2026
Zacks Investment ResearchNeutral
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
ALMS

The Motley Fool
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
NeutralALMSFebruary 3, 2026
The Motley FoolNeutral
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
ALMS

24/7 Wall Street
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs
NeutralALMSJanuary 19, 2026
24/7 Wall StreetNeutral
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs
ALMS

The Motley Fool
An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million
NeutralALMSJanuary 17, 2026
The Motley FoolNeutral
An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million
ALMS

Zacks Investment Research
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies
NeutralALMSJanuary 7, 2026
Zacks Investment ResearchNeutral
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies
ALMS

Stocktwits
Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ‘Win’ — Analysts See Best-In-Class Potential
NeutralALMSJanuary 7, 2026
StocktwitsNeutral
Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ‘Win’ — Analysts See Best-In-Class Potential
ALMS

The Motley Fool
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib
NeutralALMSJanuary 6, 2026
The Motley FoolNeutral
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib
ALMS
About Alumis Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees237
CEOMr. Martin Babler Ph.D.
IPO DateJun 28, 2024
HeadquartersSouth San Francisco, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Martin Babler Ph.D. | President, CEO & Chairman | 1965 |
| Dr. David M. Goldstein Ph.D. | Chief Scientific Officer | 1966 |
| Dr. Jorn Drappa M.D., Ph.D. | Chief Medical Officer & Head of Research and Development | 1965 |
| Mr. John R. Schroer C.F.A. | Chief Financial Officer | 1965 |
| Ms. Sanam Pangali J.D. | Chief Legal Officer & Corporate Secretary | 1984 |
| Mr. Roy C. Hardiman J.D. | Chief Business & Strategy Officer | 1960 |
| Ms. Claire Langrish Ph.D. | Senior VP & Head of Immunology and Translational Science | — |
| Mr. Philip Nunn Ph.D. | Senior VP of Pharmacology & Project Team Leader | — |
| Mr. Mark Bradley | Chief Development Officer | 1966 |
| Mr. Kolbot By Ph.D. | Senior VP & Head of Technical Operations | — |
Fundamentals
Valuation
Market cap$918.99M
Price-to-sales ratio127.55
Price-to-book value2.09
Price-earnings ratio-2.10
Return on Equity-55.00%
Return on Sales-2928.00%
Return on Assets-44.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-3.85
Income Statement
Average volume4,668,590
EBITDA$-240.44M
1 year high (52w)$31.35
1 year low (52w)$3.76
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsNeutral5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
5 Wall Street Analyst Ratings
BUY
80% Buy
20% Hold
0% Sell
Target price
$26.50
Est return
273.24%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | +0.0 | -1.9 | +0.1 | -12.5 | +6.1 | -18.1 | -5.0 | |||||
| 2025 | -9.0 | -37.5 | +35.2 | -42.8 | -8.6 | -8.8 | +37.1 | +12.3 | -15.1 | +17.0 | +68.2 | +32.8 |
| 2026 | +173.5 | +12.4 | -25.9 | +8.6 | -14.2 | +38.4 | +6.0 | -16.5 | -25.0 |



